Veterinary Medicines

Ingelvac PRRS MLV, lyofilisaat en suspendeervloeistof voor suspensie voor injectie voor varkens

Authorised
  • Porcine reproductive and respiratory syndrome virus, strain VR 2332, Live
Download as PDF

Product identification

Medicine name:
Ingelvac PRRS MLV, lyofilisaat en suspendeervloeistof voor suspensie voor injectie voor varkens
Active substance:
  • Porcine reproductive and respiratory syndrome virus, strain VR 2332, Live
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Porcine reproductive and respiratory syndrome virus, strain VR 2332, Live
    79432.80
    unit(s)
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AD03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Legal basis not covered by Directive 2001/82/EC
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Vetmedica GmbH
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 8749
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 28/02/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."